BRPI0808090A2 - Composto, composição farmacêutica, e, método in vivo para medir depósitos de amilóide em um paciente - Google Patents
Composto, composição farmacêutica, e, método in vivo para medir depósitos de amilóide em um pacienteInfo
- Publication number
- BRPI0808090A2 BRPI0808090A2 BRPI0808090-9A2A BRPI0808090A BRPI0808090A2 BR PI0808090 A2 BRPI0808090 A2 BR PI0808090A2 BR PI0808090 A BRPI0808090 A BR PI0808090A BR PI0808090 A2 BRPI0808090 A2 BR PI0808090A2
- Authority
- BR
- Brazil
- Prior art keywords
- amyloid deposits
- patient
- compound
- pharmaceutical composition
- measuring
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000037259 Amyloid Plaque Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 229940054051 antipsychotic indole derivative Drugs 0.000 abstract 2
- 238000003384 imaging method Methods 0.000 abstract 2
- 150000002475 indoles Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 210000004556 brain Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, E, MÉTODO IN VIVO PARA MEDIR DEPÓSITOS DE AMILÓIDE EM UM PACIENTE. A presente invenção diz respeito a novos derivados de indol asubstituídos por 2-heteroarila, seus precursores e usos terapêuticos de tais compostos, tendo a fórmula estrutural (Ia) abaixo: e ao seu sal farmaceuticamente aceitável, composições e métodos de uso. Além disso, a invenção diz respeito a novos derivados de indol substituídos por 2-heteroarila que são adequados para formar imagem de depósitos de amilóide em pacientes vivos, suas composições, métodos de uso e processos para fabricar tais compostos. Mas especificamente, a presente invenção diz respeito a um método de formar imagem de depósitos de amilóide em cérebro in vivo para permitir o diagnóstico antemortem do mal de Alzheimer como medir a eficácia clínica de agentes terapêuticos para o mal de Alzheimer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89315107P | 2007-03-06 | 2007-03-06 | |
| PCT/SE2008/050242 WO2008108729A1 (en) | 2007-03-06 | 2008-03-05 | Novel 2-heteroaryl substituted indoles 695 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0808090A2 true BRPI0808090A2 (pt) | 2014-06-17 |
Family
ID=39738509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0808090-9A2A BRPI0808090A2 (pt) | 2007-03-06 | 2008-03-05 | Composto, composição farmacêutica, e, método in vivo para medir depósitos de amilóide em um paciente |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100098631A1 (pt) |
| EP (1) | EP2121655A4 (pt) |
| JP (1) | JP2010520275A (pt) |
| KR (1) | KR20090115954A (pt) |
| CN (1) | CN101636395A (pt) |
| AU (1) | AU2008221667A1 (pt) |
| BR (1) | BRPI0808090A2 (pt) |
| CA (1) | CA2680055A1 (pt) |
| MX (1) | MX2009009113A (pt) |
| RU (1) | RU2009133256A (pt) |
| WO (1) | WO2008108729A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009155017A2 (en) | 2008-05-30 | 2009-12-23 | Merck & Co., Inc. | Novel substituted azabenzoxazoles |
| AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| PA8843701A1 (es) * | 2008-09-29 | 2010-05-26 | Abbott Lab | Derivados de indolina y métodos para usarlos |
| ES2620177T3 (es) | 2009-10-15 | 2017-06-27 | Guerbet | Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas |
| CN114380731B (zh) * | 2022-03-09 | 2024-07-02 | 台州学院 | 一种kcnq钾离子通道激动剂、药物组合物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040058111A (ko) * | 2001-04-23 | 2004-07-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 아밀로이드 플라크 응집 억제제 및 진단 영상화제 |
| CA2438032C (en) * | 2003-03-14 | 2013-05-07 | University Of Pittsburgh | Benzothiazole derivative compounds, compositions and uses |
| AU2006251832A1 (en) * | 2005-05-27 | 2006-11-30 | Queen's University At Kingston | Treatment of protein folding disorders |
-
2008
- 2008-03-05 JP JP2009552640A patent/JP2010520275A/ja active Pending
- 2008-03-05 AU AU2008221667A patent/AU2008221667A1/en not_active Abandoned
- 2008-03-05 CN CN200880007424A patent/CN101636395A/zh active Pending
- 2008-03-05 US US12/529,850 patent/US20100098631A1/en not_active Abandoned
- 2008-03-05 EP EP08724189A patent/EP2121655A4/en not_active Withdrawn
- 2008-03-05 CA CA002680055A patent/CA2680055A1/en not_active Abandoned
- 2008-03-05 WO PCT/SE2008/050242 patent/WO2008108729A1/en not_active Ceased
- 2008-03-05 MX MX2009009113A patent/MX2009009113A/es not_active Application Discontinuation
- 2008-03-05 KR KR1020097018582A patent/KR20090115954A/ko not_active Withdrawn
- 2008-03-05 BR BRPI0808090-9A2A patent/BRPI0808090A2/pt not_active IP Right Cessation
- 2008-03-05 RU RU2009133256/04A patent/RU2009133256A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101636395A (zh) | 2010-01-27 |
| WO2008108729A1 (en) | 2008-09-12 |
| MX2009009113A (es) | 2009-09-04 |
| KR20090115954A (ko) | 2009-11-10 |
| EP2121655A4 (en) | 2010-09-22 |
| RU2009133256A (ru) | 2011-04-20 |
| CA2680055A1 (en) | 2008-09-12 |
| JP2010520275A (ja) | 2010-06-10 |
| US20100098631A1 (en) | 2010-04-22 |
| EP2121655A1 (en) | 2009-11-25 |
| AU2008221667A1 (en) | 2008-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088645A (es) | Nuevos benzotiazoles sustituidos con heteroaril | |
| UY30419A1 (es) | Nuevos benzoxazoles heteroaril sustituidos | |
| BRPI0808503B8 (pt) | composto, uso de um composto, e, composição farmacêutica | |
| MX2009007487A (es) | Derivados de imidazo[1,2-a]piridina substituidos de heteroarilo novedosos. | |
| CN111039939B (zh) | 用作蛋白质聚集抑制剂的杂芳基酰胺 | |
| ES2962890T3 (es) | Uso del cannabidiol en el tratamiento del complejo de esclerosis tuberosa | |
| WO2009155017A3 (en) | Novel substituted azabenzoxazoles | |
| MX375282B (es) | Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares. | |
| ES2584653T3 (es) | Sonda para la obtención de imágenes de Tau | |
| NI201100100A (es) | Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1. | |
| BR112014021634A8 (pt) | inibidores de serina/treonina quinase,composições que os compreendem, seus usos e seus processos de preparação, e método de inibir a atividade da proteína quinase erk em uma célula | |
| CL2012000708A1 (es) | Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades. | |
| BRPI0113470B8 (pt) | composto de ligação amilóide, composição farmacêutica e métodos de síntese de composto, de detecção in vivo de depósitos amilóides num indivíduo e em tecido humano ou animal, de quantificação de depósito amilóide em tecido de biópsia ou postmortem e de distinção de um cérebro de doença de alzheimer de um cérebro normal | |
| BRPI0515175A (pt) | método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer | |
| TW201444860A (zh) | 脲嘧啶核苷衍生物、組合物及使用方法 | |
| BRPI0917147B8 (pt) | composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto | |
| BRPI0808090A2 (pt) | Composto, composição farmacêutica, e, método in vivo para medir depósitos de amilóide em um paciente | |
| EA200801529A1 (ru) | Кристаллические формы 1-бензоил-4-[2-[4-метокси-7-(3-метил-1h-1,2,4-1-ил)-1-[(фосфонокси)метил]-1h-пирроло[2,3-c]пиридин-3-ил]-1,2-диоксоэтил]пиперазина | |
| WO2017132263A1 (en) | Phosphonate-drug conjugates | |
| ES2875058T3 (es) | Uso de compuestos de fenoxipropilamina para tratar la depresión | |
| MX2025010406A (es) | Aglutinantes de alfa-sinucleina y metodos de uso | |
| MX2025009562A (es) | Enlazadores de alfa-sinucleína y métodos de uso | |
| BR112021012834A2 (pt) | Derivados de pirimidina para a prevenção e tratamento de infecções bacterianas gram-negativas | |
| BRPI0606750A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e,composição farmacêutica | |
| JP2019522642A (ja) | ビスホスホネートの骨格除去 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 4A, 5A E 6A ANUIDADES. |
|
| B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A, 7A, 8A, 9A, 10A, 11A E 12A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |